In a clinic, the decision to order an MRI for a patient’s back pain is often a reflex, a default step in a well-worn pathway. The resulting scan, however, is frequently unnecessary, exposing the patient to cost and anxiety without improving their outcome. Bia Health, a Quebec City company founded by healthcare professionals, is betting that an AI assistant can help clinicians pause and ask a more fundamental question first: is this test, or any intervention, actually relevant to this patient’s care [Perplexity Sonar Pro Brief]?
Their product, Bia Assistant, is an AI clinical tool designed to support diagnostic and intervention decisions, starting with musculoskeletal conditions. The company recently secured C$2.15 million in pre-seed funding to scale it, a round that underscores a quiet pivot from a trusted education business into the fraught but critical arena of clinical AI [BetaKit, October 2026]. For CEO and co-founder Anne-Sophie Paquet, a physiotherapist, the mission is less about deploying technology and more about codifying clinical wisdom to keep patient care on the most effective path.
A clinical wedge built on trust
Bia Health did not begin with an algorithm. It started in 2016 as a provider of continuing education and a medical-content library for healthcare professionals in Quebec [BetaKit, October 2026]. This foundation gave the company a crucial asset: an established relationship with thousands of physiotherapists, doctors, and other clinicians who already used its platform for learning [Perplexity Sonar Pro Brief]. That trust is the wedge for introducing Bia Assistant into the clinical workflow. The tool is positioned not as a replacement for clinician judgment, but as a support system that references guidelines and evidence to help determine the ‘care relevance’ of a proposed test or referral [Perplexity Sonar Pro Brief].
This focus on frontline care, rather than a direct-to-consumer application, aligns with a growing regulatory push for tools that aid clinical decision-making. The company’s approach is inherently conservative, aiming to integrate into existing workflows to reduce variability and waste. The reported C$500,000 in annual recurring revenue from its education business provides a stable base from which to launch this more ambitious clinical product [BetaKit, October 2026].
The funding and the team behind the pivot
The October 2026 financing is structured to support growth while managing risk. Of the total C$2.15 million, C$1.4 million is debt provided by Finalta Capital. The equity portion was led by Anges Québec, with participation from Desjardins’ Startup en résidence program and physician angel investors [BetaKit, October 2026]. The use of debt suggests a capital-efficient model, leveraging the company’s existing revenue stream to fund its expansion into AI.
The leadership team is deeply rooted in clinical practice. Anne-Sophie Paquet, the CEO, is a practicing physiotherapist, ensuring the product is built with an intimate understanding of the clinician’s environment and the patient’s journey. Co-founder Amélie Fournier-Belley serves as Chief Product Officer [Perplexity Sonar Pro Brief]. Their decade-long operation in the Quebec healthcare ecosystem is a tangible credential, one that pure-play AI startups often lack.
| Role | Name | Background |
|---|---|---|
| Co-founder, CEO | Anne-Sophie Paquet | Physiotherapist [Perplexity Sonar Pro Brief] |
| Co-founder, CPO | Amélie Fournier-Belley | Product leadership [Perplexity Sonar Pro Brief] |
Navigating the risks of clinical AI
For all its grounded origins, Bia Health is stepping into a field dense with regulatory and adoption hurdles. The company’s path is lined with specific challenges that will test its model.
- Clinical validation. The most significant hurdle is generating peer-reviewed evidence that Bia Assistant improves patient outcomes or reduces unnecessary imaging in real-world settings. An AI tool’s utility in a pilot is different from its proven impact across diverse health systems. The company’s next milestones will likely involve publishing such data.
- Regulatory pathway. While positioned as a decision-support tool, any software intended to inform diagnosis or treatment recommendations attracts scrutiny from bodies like Health Canada and the FDA. Navigating a clear regulatory classification will be essential for scaling beyond early adopters.
- Market expansion. Bia’s stronghold is in Quebec, built on a foundation of local professional relationships. Translating that success to other provinces or countries requires adapting to different clinical guidelines, reimbursement models, and healthcare IT infrastructures. The debt-heavy financing round may limit the aggressive sales spend sometimes used to crack new markets.
The company’s most plausible answer to these risks is its foundational strategy: move slowly, use existing trust, and prove value in focused clinical areas before broadening its claim. Its musculoskeletal starting point is a deliberate choice, a contained domain with high volumes of potentially low-value imaging.
The next twelve months
The immediate use of proceeds is clear: deploy Bia Assistant to more clinicians. The coming year will be measured in pilots and partnerships, likely within the Quebec healthcare system initially. Key milestones to watch will be the announcement of a first major institutional healthcare partner and the publication of any preliminary clinical validation data. A subsequent funding round, likely a seed equity round, would signal confidence from new investors and provide capital to address the expansion challenges beyond the company’s home region.
For patients with musculoskeletal pain, the standard of care today often involves a frustrating cycle. A primary care visit for back or shoulder pain can quickly lead to a referral for imaging, a wait for results, and a follow-up that may simply confirm the need for physiotherapy or pain management. This pathway consumes time and resources while delaying the start of effective, conservative treatment. Bia Health’s bet is that by arming the clinician at the first point of contact with better decision support, that cycle can be shortened. The patient gets a more relevant care plan faster, and the system avoids the cost of a scan that wasn’t needed. It’s a humane goal, one that places the patient’s outcome ahead of the technology’s novelty. The next step is proving it works at scale.
Sources
- [BetaKit, October 2026] Bia Health raises $2.15 million for AI to reduce unnecessary medical interventions | https://betakit.com/bia-health-raises-2-15-million-for-ai-to-reduce-unnecessary-medical-interventions/
- [Perplexity Sonar Pro Brief] Bia Health company briefing
- [Bia - Empowering Healthcare Professionals in Musculoskeletal Care] Company website
- [Podcast | Bia] Company podcast discussion on pivot